ERBB2 and neoplasm: Some immunotherapies are based on immunomodulation and the addition of exogenous molecules, such as cytokines (e.g., IL-2) or antibodies targeting tumor-immune cell interactions (e.g., PD-1/PD-L1 or HER-2).